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Introduction
Large spectrum antibiotics have to be considered as first
treatment of infection in ICU patients.
Objectives
To evaluate the antibiotic treatments in ICU patients
and to compare treatments on admission and during
ICU stay.
Methods
A Six-month prospective study in 5 ICUs of a hospital
totalizing 44 ICU beds. Antibiotic treatments were
divided in three groups: treatment started before ICU
admission (1), treatments started the day of ICU admis-
sion (2) and treatments initiated during ICU stay (3).
The type of beta-lactam antibiotics (BA) used was listed
at the start of treatment and after 3 days.
Results
459 treatments given to 363 patients among 1131 hospi-
talized patients were analyzed. There were respectively
131, 167 and 161 treatments in group 1, 2 and 3. After
3 days, 79 (17.2%) treatments could be stopped because
of no infections and 129 (28.1%) were changed mostly
for streamlining. Table 1 shows the number of treat-
ment with BA according to groups and to the time of
treatment.
There was a tendency to use less BA during ICU stay,
the difference was significant only at the start of treat-
ment (p = 0.027). If we consider ampicillin, temocillin,
penicillin, flucloxacillin and 2nd -generation cephalos-
porin as molecule with narrow spectrum of activity, these
molecules were significantly more used after three days
of treatment (p < 0.0001). Interestingly this difference
already existed at the start of treatment when group 3
was compared to the two others (p = 0.0159). Among the
459 treatments, there were, in 49 patients, 51 inappropri-
ate treatments according to the bacteriological results,
16 (12%) in group 1, 17 (10%) in group 2 and 18 (11%) in
group 3 (p = 0.857). The ICU mortality was not different
between those patients (11/49 = 22%) and the others (77/
314 = 24.5%) (p = 0859).
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After 3 days n =
96 (group 1)
After 3 days n =
133 (group 2)





2 (1,5%) 2 (1,2%) 3 (1,9%) 4 (4,2%) 9 (6,8%) 10 (6,8%)
Penicillin 1 (0,8%) 1 (0,6%) 0 (0%) 1 (1%) 4 (3%) 0 (0%)
Flucloxacillin 8 (6%) 0 (0%) 10 (6%) 11 (11,5%) 5 (3,8%) 11 (6,8%)
Amoxi-Clav 15 (11,5%) 35 (21%) 15 (9,3%) 1 (1%) 13 (9,8%) 7 (4,7%)
Pipera-Tazo 42 (32,1%) 54 (32,3%) 32 (19,9%) 17 (17,7%) 21 (15,8%) 13 (8,8%)
Cephal 2G 3 (2,3%) 5 (3%) 9 (5,6%) 8 (8,3%) 11 (8,3%) 15 (10,1%)
Cephal 3G 14 (10,7%) 34 (20,4%) 35 (21,7%) 19 (19,8%) 20 (15%) 26 (17,6%)
Cephal 4G 7 (5,3%) 1 (0,6%) 2 (1,2%) 2 (2,1%) 1 (0,8%) 1 (0,7%)
Carbapenem 17 (13%) 15 (8,9%) 19 (11,8%) 10 (10,4%) 12 (9%) 14 (9,5%)
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Conclusions
Beta-lactam antibiotics remain the cornerstone of anti-
bacterial therapy. A cautious strategy with narrow spec-
trum beta-lactam antibiotics could be supported in ICU
patients when possible.
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